Healthcare
•1072 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (1072)
%
| Company | Market Cap | Price |
|---|---|---|
|
NiQuitin is an OTC nicotine replacement therapy product within Perrigo's portfolio.
|
$2.92B |
$21.25
-1.67%
|
|
SYFOVRE is an ophthalmic drug (intravitreal pegcetacoplan) approved for geographic atrophy, representing the company's core marketed product.
|
$2.86B |
$22.76
-1.85%
|
|
TRS-RenTelco provides electronic test/diagnostic equipment rental and related services.
|
$2.81B |
$114.00
-1.77%
|
|
Immunology therapeutics focus: ARCALYST and pipeline IL-1 pathway inhibitors place Kiniksa in the immunology/anti-inflammatory therapeutics space.
|
$2.76B |
$37.89
-0.58%
|
|
Directly manufactures and sells neuromodulation devices including VNS Therapy for epilepsy and proximal HGNS for OSA.
|
$2.76B |
$50.69
-2.14%
|
|
Ascentage Pharma’s core business is oncology-focused biotechnology with approved and pipeline small-molecule cancer therapies (olverembatinib, lisaftoclax, alrizomadlin).
|
$2.75B |
$34.94
-5.05%
|
|
Lorundrostat is an orally administered, small-molecule therapeutic, aligning Mineralys with the 'Oral Small Molecule Therapeutics' category.
|
$2.75B |
$42.16
+6.98%
|
|
Organon's Hadlima, Renflexis, and Ontruzant biosimilars are core revenue drivers.
|
$2.75B |
$10.65
+0.80%
|
|
IMVT-1402 is a monoclonal antibody therapeutic targeting FcRn, central to Immunovant's drug platform.
|
$2.75B |
$16.07
-0.77%
|
|
Core CNS neuropsychiatric drug development focus aligns with Qelbree, GOCOVRI, ONAPGO, and ZURZUVAE and the pipeline assets.
|
$2.74B |
$49.00
-0.79%
|
|
Veracyte provides laboratory testing services and advisory/clinical-evidence support for test development and deployment.
|
$2.73B |
$34.80
-0.66%
|
|
Directly develops and commercializes allogeneic mesenchymal stromal cell therapies (RYONCIL and rexlemestrocel-L).
|
$2.72B |
$2.12
|
|
Laboratory Testing & Advisory Services: includes bench-scale refining/testing activities tied to processing trials (via partners).
|
$2.68B |
$7.41
+2.21%
|
|
Provides diagnostic testing and advisory services within its occupational health centers and onsite clinics.
|
$2.67B |
$20.82
+0.77%
|
|
Beam Therapeutics is built around a gene therapy platform (base editing) and develops therapeutic programs that edit genes to treat diseases.
|
$2.65B |
$26.32
-7.58%
|
|
Scientific segment focuses on specialty temperature-controlled equipment used in healthcare and labs, aligning with diagnostic equipment.
|
$2.62B |
$217.17
-1.72%
|
|
Core business focus on rare-disease therapies (Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease) sold/commercialized directly.
|
$2.56B |
$8.30
|
|
Dentsply Sirona manufactures dental imaging devices, CAD/CAM systems, and other dental practice equipment.
|
$2.49B |
$12.50
+2.21%
|
|
Company develops oral small-molecule therapeutics (bitopertin and DISC pipeline), a major product category in pharma.
|
$2.42B |
$69.90
-0.87%
|
|
Lead product ANKTIVA is an oncology immunotherapy (cytokine fusion protein) and core revenue driver.
|
$2.40B |
$2.54
+0.20%
|
|
ARQT's ZORYVE is a non-steroidal topical immunomodulatory therapy for inflammatory dermatologic conditions, aligning with Immunology Therapeutics.
|
$2.39B |
$20.05
-3.28%
|
|
Galleri is a liquid biopsy-based cfDNA methylation test that detects multiple cancers, fitting the Liquid Biopsy investable theme.
|
$2.38B |
$66.13
-7.38%
|
|
Company develops immunology-focused biologics (antibodies) for inflammatory and immune-mediated diseases.
|
$2.37B |
$39.88
-0.18%
|
|
Agios' lead product mitapivat and pipeline tebapivat are oral small‑molecule therapeutics for rare hematologic diseases.
|
$2.35B |
$40.61
-4.47%
|
|
Haemonetics' TEG 6s hemostasis analyzer is a core hospital diagnostic device.
|
$2.35B |
$48.85
-2.81%
|
|
Catalyst's core business is developing and commercializing rare-disease therapies (FIRDAPSE, AGAMREE, FYCOMPA), aligning with Biotech - Rare Diseases.
|
$2.33B |
$19.13
-2.60%
|
|
Tinlarebant is a lead oral small-molecule therapeutic (LBS-008) targeting retinal diseases.
|
$2.31B |
$79.28
+1.03%
|
|
IDEAYA develops targeted cancer therapies and biomarker-driven precision oncology platforms, fitting Biotech - Oncology.
|
$2.30B |
$26.24
-2.42%
|
|
Medi-spa equipment and devices used for premium wellness treatments on cruise ships constitute medical/surgical equipment usage.
|
$2.27B |
$22.12
-0.85%
|
|
Galapagos is pivoting to and actively developing cell therapies (CAR-T) for oncology, which is the core product focus.
|
$2.25B |
$34.10
+0.86%
|
|
Company is a large-cap pharmaceutical with a diversified portfolio and core revenue from prescription medicines and ophthalmic products.
|
$2.24B |
$6.05
-4.87%
|
|
Denali's TransportVehicle (TV) platform is a proprietary drug delivery platform designed to cross the blood-brain barrier, representing a major Drug Delivery Platforms investable theme.
|
$2.23B |
$15.37
-5.12%
|
|
Inspire Medical Systems' flagship product is a neuromodulation device (Inspire V) delivering hypoglossal nerve stimulation for OSA.
|
$2.22B |
$75.17
-6.27%
|
|
Travere's lead product FILSPARI (sparsentan) targets rare kidney diseases (IgA nephropathy) and is the core commercial/late-stage product, classed under Rare Diseases.
|
$2.21B |
$24.85
+2.10%
|
|
Directly develops and commercializes gene therapies (ELEVIDYS) and gene-targeted modalities; core product category in Sarepta's business.
|
$2.17B |
$22.11
-4.49%
|
|
PROCEPT's Aquablation robotic systems are surgical devices used in urology procedures (BPH) and are sold as capital surgical equipment.
|
$2.17B |
$39.15
+1.77%
|
|
Direct product category: Mesoblast's core offering is allogeneic mesenchymal lineage cell therapies (Ryoncil, rexlemestrocel-L, Revascor), which fit 'Biotech - Cell Therapy'.
|
$2.11B |
$18.32
-4.03%
|
|
Company's core oncology MRD diagnostics (clonoSEQ) and immune medicine platform target cancer monitoring and treatment.
|
$2.03B |
$13.36
-3.68%
|
|
Strategic focus on oncology programs within the biotech/pharmaceutical pipeline (precision oncology).
|
$2.02B |
$4.81
-3.99%
|
|
Ophthalmology Devices captures devices used in eye care and diagnostics, relevant to National Vision's eye-care operations.
|
$2.02B |
$25.56
-6.37%
|
|
Directly provides hospital-based inpatient and outpatient medical care services (acute care, urgent care, physician practice networks).
|
$2.01B |
$14.05
-2.57%
|
|
Generic Drugs is a core revenue driver for ANI with multiple new product launches and CGT-related exclusivity driving the Generics & Other segment.
|
$1.99B |
$90.17
-1.51%
|
|
YUTREPIA and Liquidia's cardiovascular prostacyclin program place the company in the Cardiovascular Drugs category.
|
$1.98B |
$23.19
-5.19%
|
|
ELUTYX is a proprietary drug-delivery platform powering sustained release, underpinning AXPAXLI, a core retinal program.
|
$1.94B |
$12.48
+1.88%
|
|
Spinal implants and fixation devices place Alphatec squarely in the Orthopedic Devices category.
|
$1.92B |
$13.14
-4.58%
|
|
Directly produces vascular surgical devices (grafts, patches, shunts, catheters) categorized as Surgical Equipment.
|
$1.90B |
$86.56
+2.82%
|
|
Antibody libraries for drug discovery reflect an antibody discovery platform offering.
|
$1.87B |
$31.19
-6.39%
|
|
Lead asset bezuclastinib is an oral small-molecule tyrosine kinase inhibitor targeting KIT D816V, aligning with the Oral Small Molecule Therapeutics category.
|
$1.85B |
$16.27
|
|
AtriCure sells surgical equipment such as the EnCompass Clamp and related devices used in cardiac surgery and ablation procedures.
|
$1.79B |
$36.18
-0.47%
|
|
QuidelOrtho directly manufactures and sells diagnostic instruments used in laboratories for disease detection.
|
$1.78B |
$26.37
-6.56%
|
|
Gedatolisib is a pan-PI3K/mTOR inhibitor targeting oncology indications, aligning with Biotech - Oncology as the direct product category.
|
$1.74B |
$46.07
-6.25%
|
|
Directly manufactures orthopedic implants and devices (hip/knee systems) under Enovis Recon, aligning with Orthopedic Devices.
|
$1.74B |
$30.20
-0.85%
|
|
Celldex's lead product barzolvolimab is a humanized monoclonal antibody targeting KIT, a core monoclonal antibody therapeutic.
|
$1.74B |
$26.14
+1.79%
|
|
KIMMTRAK is a leading oncology therapy (metastatic uveal melanoma) and Immunocore is expanding an ImmunTAX-based oncology pipeline, making Biotech - Oncology the core investable theme.
|
$1.72B |
$34.27
-0.95%
|
|
Laboratory testing & advisory services related to testing facilities and regulatory compliance.
|
$1.72B |
$45.83
-5.10%
|
|
Company's core revenue derives from cardiology devices (e.g., On-X heart valve, arch repair devices).
|
$1.72B |
$40.20
-1.18%
|
|
Viridian's lead assets are monoclonal antibodies (veligrotug and VRDN-003), placing the company in Monoclonal Antibody Therapeutics.
|
$1.71B |
$20.99
-3.94%
|
|
Intellia's core offerings are in vivo CRISPR gene therapy programs, representing Biotech - Gene Therapy.
|
$1.69B |
$16.31
-1.33%
|
|
Provides patient monitoring capabilities (remote vital-sign tracking) as part of in-home care services.
|
$1.69B |
$8.65
-1.82%
|
|
Directly provides Laboratory Testing & Advisory Services, including testing, regulatory advisory, and related analytical capabilities.
|
$1.68B |
$13.75
-1.08%
|
|
Directly developing immunology therapeutics with atacicept (dual BAFF/APRIL inhibitor) for autoimmune diseases.
|
$1.67B |
$26.14
-0.04%
|
|
STOKE is targeting rare genetic diseases (haploinsufficiency) with lead programs for Dravet syndrome and ADOA, a core Rare Diseases focus.
|
$1.65B |
$30.19
-2.46%
|
|
Directly applies to Kv7 ion channel modulation and TRPM3 antagonism platforms powering CNS, pain, and neuroimmune programs.
|
$1.61B |
$15.80
-9.97%
|
|
Core product category: oral small molecule therapeutics.
|
$1.61B |
$28.00
+10.54%
|
|
Vericel's core products are autologous cell therapies (MACI, Epicel) and related biologic offerings, making 'Biotech - Cell Therapy' a direct representation of their primary manufacturing focus.
|
$1.60B |
$31.85
-3.51%
|
|
FORCE platform enables targeted delivery of genetic payloads to muscle/CNS, making Dyne a direct developer of gene therapy–like therapeutics.
|
$1.60B |
$14.05
-0.57%
|
|
Edgewise's core offerings are orally administered small-molecule therapeutics (sevasemten, EDG-7500).
|
$1.59B |
$15.11
-5.92%
|
|
SEM’s core offerings are hospital-based post-acute care services (Inpatient Rehabilitation Hospitals, Critical Illness Recovery Hospitals, and Outpatient Rehabilitation clinics), i.e., hospital services.
|
$1.59B |
$12.35
-2.45%
|
|
Direct product: vaccines for animal health as part of Phibro's Animal Health segment.
|
$1.57B |
$38.04
+0.34%
|
|
TXG manufactures and sells laboratory instrumentation (Chromium, Spatial platforms) used for genomic analysis, i.e., diagnostic equipment.
|
$1.55B |
$12.39
+5.45%
|
|
Arcus Biosciences operates as a oncology-focused biotech developing cancer therapies (HIF-2α inhibitor casdatifan and IO antibodies).
|
$1.55B |
$14.60
-4.20%
|
|
LUPKYNIS is an oral small-molecule therapeutic, aligning with the 'Oral Small Molecule Therapeutics' category.
|
$1.53B |
$11.35
+0.44%
|
|
Harmony's pipeline centers on oral small molecule CNS therapies (narcolepsy/EDS, rare neuropsychiatric indications) and WAKIX is an oral small molecule; multiple assets in development follow this format.
|
$1.52B |
$26.54
-1.19%
|
|
ORLADEYO is BioCryst's flagship oral small-molecule therapeutic for hereditary angioedema, forming the core product and revenue driver.
|
$1.51B |
$7.22
-0.48%
|
|
Avadel directly markets LUMRYZ, an oral small-molecule therapeutic for narcolepsy.
|
$1.51B |
$15.49
-0.61%
|
|
UFPT directly designs and manufactures medical device consumables, including sterile, single-use components and related sterile packaging elements.
|
$1.50B |
$195.22
+0.25%
|
|
NovoCure's TTFields oncology therapy platform is used to treat multiple cancer indications, aligning with Oncology-focused biotech/device ecosystems.
|
$1.50B |
$13.49
-5.99%
|
|
The Cloudbreak platform represents a drug delivery platform technology (Drug Delivery Platforms) used to create Drug-Fc Conjugates with extended half-life for therapeutics.
|
$1.47B |
$113.05
-2.88%
|
|
AbCellera's differentiated AI-powered platform is the core product enabling discovery of antibodies, including GPCRs/ion channels and T-cell engager platforms.
|
$1.45B |
$5.03
+2.86%
|
|
Core focus on oncology therapeutics (tumor-activated immunotherapies) under Biotech - Oncology.
|
$1.45B |
$24.44
+3.25%
|
|
XT Series automated dispensing systems are hardware-based medical device components.
|
$1.43B |
$30.62
+0.39%
|
|
Azenta offers laboratory testing and advisory services through its GENEWIZ Genomics Services platform, including sequencing and related data generation.
|
$1.41B |
$30.73
-3.30%
|
|
Novavax directly develops and commercializes vaccines (e.g., Nuvaxovid) and licenses its Matrix-M adjuvant/platform, making 'Vaccines' the primary investable product category.
|
$1.38B |
$8.55
+2.64%
|
|
Revuforj is an oral small-molecule therapeutic (menin inhibitor), aligning with 'Oral Small Molecule Therapeutics'.
|
$1.38B |
$16.06
-1.35%
|
|
Evotec provides outsourced drug discovery and preclinical development services as a CRO.
|
$1.38B |
$7.28
|
|
Harrow directly develops and sells ophthalmic drugs (VEVYE, IHEEZO, TRIESENCE, BYQLOVI) and biosimilars in the ophthalmic space, i.e., ophthalmic drugs.
|
$1.38B |
$37.48
-8.02%
|
|
Directly manufactures and sells surgical equipment including the SSi Mantra robotic system and instruments.
|
$1.35B |
$6.95
-7.09%
|
|
STAAR primarily designs, manufactures, and sells ophthalmology devices (implantable lenses) used in refractive surgery, categorized under Ophthalmology Devices.
|
$1.32B |
$26.75
-0.26%
|
|
Company develops small-molecule oral CFTR modulators (SION-719, SION-451) targeting CF; a core oral small molecule therapeutics product category.
|
$1.32B |
$29.93
-0.28%
|
|
CNMD directly manufactures surgical equipment used in operating rooms, including AirSeal, Buffalo Filter, and related disposable instruments.
|
$1.32B |
$42.68
-6.42%
|
|
Neogen directly manufactures diagnostic equipment and platforms (e.g., MDS pathogen detection system and Petrifilm automated reader) used for food and animal safety testing.
|
$1.31B |
$6.04
-12.21%
|
|
BHE designs and manufactures medical device components/subsystems for regulated markets.
|
$1.30B |
$35.97
-4.36%
|
|
Xeris Biopharma is a pharmaceutical company commercializing drugs (Recorlev, Gvoke, Keveyis), fitting the Large Cap Pharma category.
|
$1.28B |
$7.99
-2.44%
|
|
Nuvation Bio is developing oncology therapies (IBTROZI and Safusidenib) and has a pipeline focused on cancer indications.
|
$1.27B |
$3.74
-1.84%
|
|
PBH and Wolfram PSP represent rare diseases addressed by Amylyx's pipeline, aligning with the Biotech - Rare Diseases theme.
|
$1.27B |
$14.26
-1.11%
|
|
Zymeworks directly develops and licenses Antibody-Drug Conjugates (ADCs), including zanidatamab and WHOLLY-OWNED ADCs like ZW191, ZW251, and ZW220.
|
$1.26B |
$18.06
+4.39%
|
|
Lead asset pacibetKITug is a fully human monoclonal antibody targeting IL-6, placing Tourmaline Bio in immunology therapeutics.
|
$1.23B |
$47.75
|
|
Motiva Implants are prosthetic breast implants manufactured and sold by ESTA for aesthetics and reconstruction.
|
$1.22B |
$41.43
-2.03%
|
|
Cardiology ablation catheters and surgical AF devices (e.g., 360 Catheter, AF Clamp) are directly categorized as Cardiology Devices.
|
$1.22B |
$18.12
+2.66%
|
|
Immunome operates as a biotechnology company focused on oncology, aligning with the Biotech - Oncology category.
|
$1.21B |
$13.92
-5.18%
|
Showing page 3 of 11 (1072 total stocks)
Loading industry metrics...
Loading comparison data...
